Loss of biglycan enhances thrombin generation in Apolipoprotein E-deficient mice: Implications for inflammation and atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 5, 2016, Pages e41-e50

  Grandoch, Maria ^a   Kohlmorgen, Christina ^a   Melchior Becker, Ariane ^a   Feldmann, Kathrin ^a   Homann, Susanne ^a   Müller, Julia ^a   Kiene, Lena Sophia ^a   Zeng Brouwers, Jinyang ^b   Schmitz, Friederike ^a   Nagy, Nadine ^a   Polzin, Amin ^a   Gowert, Nina S ^a   Elvers, Margitta ^a   Skroblin, Philipp ^c   Yin, Xiaoke ^c   Mayr, Manuel ^c   Schaefer, Liliana ^b   Tannock, Lisa R ^d   Fischer, Jens W ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

atherosclerosis; biglycan; blood platelets; inflammation; thrombin

Indexed keywords

APOLIPOPROTEIN E; ARGATROBAN; BIGLYCAN; HEPARIN COFACTOR II; THROMBIN; ANTITHROMBIN; BGN PROTEIN, HUMAN; BGN PROTEIN, MOUSE; CYTOKINE; SERPIND1 PROTEIN, MOUSE;

ACUTE CORONARY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; GLYCOCALYX; HUMAN; IN VIVO STUDY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN FUNCTION; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; ANIMAL; AORTA; AORTIC DISEASES; BLOOD; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; GENOTYPE; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; PATHOLOGY; TIME FACTOR;

ACUTE CORONARY SYNDROME; ANIMALS; ANTITHROMBINS; AORTA; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIGLYCAN; CYTOKINES; DISEASE MODELS, ANIMAL; GENOTYPE; HEPARIN COFACTOR II; HUMANS; INFLAMMATION; MACROPHAGES; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; PLATELET ACTIVATION; THROMBIN; TIME FACTORS;

EID: 84962050631     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306973     Document Type: Article

References (42)

1. Zheng L, Martins-Green M, Molecular mechanisms of thrombin-induced interleukin-8 (IL-8/CXCL8) expression in THP-1-derived and primary human macrophages. J Leukoc Biol 2007 82 619 629. doi: 10.1189/jlb.0107009
2. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K, Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003 9 61 67. doi: 10.1038/nm810
3. Oldgren J, Wallentin L, Alexander JH, James S, Jönelid B, Steg G, Sundström J, New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-Analysis. Eur Heart J 2013 34 1670 1680. doi: 10.1093/eurheartj/eht049
4. Kornerup KN, Salmon GP, Pitchford SC, Liu WL, Page CP, Circulating platelet-neutrophil complexes are important for subsequent neutrophil activation and migration. J Appl Physiol (1985) 2010 109 758 767. doi: 10.1152/japplphysiol.01086.2009
5. Colotta F, Sciacca FL, Sironi M, Luini W, Rabiet MJ, Mantovani A, Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 1994 144 975 985
6. Aihara K, Azuma H, Takamori N, Kanagawa Y, Akaike M, Fujimura M, Yoshida T, Hashizume S, Kato M, Yamaguchi H, Kato S, Ikeda Y, Arase T, Kondo A, Matsumoto T, Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation 2004 109 2761 2765. doi: 10.1161/01.CIR.0000129968.46095.F3
7. Ise T, Aihara K, Sumitomo-Ueda Y, Yoshida S, Ikeda Y, Yagi S, Iwase T, Yamada H, Akaike M, Sata M, Matsumoto T, Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors. Hypertens Res 2011 34 225 231. doi: 10.1038/hr.2010.211
8. Shirk RA, Parthasarathy N, San Antonio JD, Church FC, Wagner WD, Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. J Biol Chem 2000 275 18085 18092. doi: 10.1074/jbc.M001659200
9. Chang MY, Potter-Perigo S, Tsoi C, Chait A, Wight TN, Oxidized low density lipoproteins regulate synthesis of monkey aortic smooth muscle cell proteoglycans that have enhanced native low density lipoprotein binding properties. J Biol Chem 2000 275 4766 4773
10. Tiede K, Melchior-Becker A, Fischer JW, Transcriptional and posttranscriptional regulators of biglycan in cardiac fibroblasts. Basic Res Cardiol 2010 105 99 108. doi: 10.1007/s00395-009-0049-8
11. Schaefer L, Macakova K, Raslik I, Micegova M, Gröne HJ, Schönherr E, Robenek H, Echtermeyer FG, Grässel S, Bruckner P, Schaefer RM, Iozzo RV, Kresse H, Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 2002 160 1181 1191. doi: 10.1016/S0002-9440(10)64937-1
12. Kolodgie FD, Burke AP, Farb A, Weber DK, Kutys R, Wight TN, Virmani R, Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. Arterioscler Thromb Vasc Biol 2002 22 1642 1648
13. Corsi A, Xu T, Chen XD, Boyde A, Liang J, Mankani M, Sommer B, Iozzo RV, Eichstetter I, Robey PG, Bianco P, Young MF, Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. J Bone Miner Res 2002 17 1180 1189. doi: 10.1359/jbmr.2002.17.7.1180
14. Babelova A, Moreth K, Tsalastra-Greul W, Zeng-Brouwers J, Eickelberg O, Young MF, Bruckner P, Pfeilschifter J, Schaefer RM, Gröne HJ, Schaefer L, Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem 2009 284 24035 24048. doi: 10.1074/jbc.M109.014266
15. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Götte M, Malle E, Schaefer RM, Gröne HJ, The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005 115 2223 2233. doi: 10.1172/JCI23755
16. Nakashima Y, Fujii H, Sumiyoshi S, Wight TN, Sueishi K, Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 2007 27 1159 1165. doi: 10.1161/ATVBAHA.106.134080
17. O'Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K, Wight TN, Chait A, Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 1998 98 519 527
18. Marzoll A, Melchior-Becker A, Cipollone F, Fischer JW, Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment? J Cell Mol Med 2011 15 232 243. doi: 10.1111/j.1582-4934.2009.00986.x
19. Tang T, Thompson JC, Wilson PG, Yoder MH, Müeller J, Fischer JW, Williams KJ, Tannock LR, Biglycan deficiency: increased aortic aneurysm formation and lack of atheroprotection. J Mol Cell Cardiol 2014 75 174 180. doi: 10.1016/j.yjmcc.2014.07.014
20. Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM, Swiatlowska P, Newman AA, Greene ES, Straub AC, Isakson B, Randolph GJ, Owens GK, KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med 2015 21 628 637. doi: 10.1038/nm.3866
21. Whinna HC, Choi HU, Rosenberg LC, Church FC, Interaction of heparin cofactor II with biglycan and decorin. J Biol Chem 1993 268 3920 3924
22. Tollefsen DM, Pestka CA, Monafo WJ, Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983 258 6713 6716
23. Mega JL, Braunwald E, Wiviott SD, ATLAS ACS 2-TIMI 51 Investigators Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012 366 9 19. doi: 10.1056/NEJMoa1112277
24. Alexander JH, Lopes RD, James S, APPRAISE-2 Investigators Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011 365 699 708. doi: 10.1056/NEJMoa1105819
25. Nagy N, Melchior-Becker A, Fischer JW, Long-Term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosis. Basic Res Cardiol 2010 105 29 38. doi: 10.1007/s00395-009-0051-1
26. Nigro J, Potter-Perigo S, Ivey ME, de Dios ST, Evanko SP, Wight TN, Little PJ, The effect of PPAR ligands to modulate glucose metabolism alters the incorporation of metabolic precursors into proteoglycans synthesized by human vascular smooth muscle cells. Arch Physiol Biochem 2008 114 171 177. doi: 10.1080/13813450802181013
27. Kinsella MG, Tsoi CK, Järveläinen HT, Wight TN, Selective expression and processing of biglycan during migration of bovine aortic endothelial cells. The role of endogenous basic fibroblast growth factor. J Biol Chem 1997 272 318 325
28. Okajima K, Antithrombin prevents endotoxin-induced pulmonary vascular injury by inhibiting leukocyte activation. Blood Coagul Fibrinolysis 1998 9 suppl 2 S25 S37
29. Kanagawa Y, Shigekiyo T, Aihara K, Akaike M, Azuma H, Matsumoto T, Molecular mechanism of type I congenital heparin cofactor (HC) II deficiency caused by a missense mutation at reactive P2 site: HC II Tokushima. Thromb Haemost 2001 85 101 107
30. Takamori N, Azuma H, Kato M, Hashizume S, Aihara K, Akaike M, Tamura K, Matsumoto T, High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation 2004 109 481 486. doi: 10.1161/01.CIR.0000109695.39671.37
31. Borissoff JI, Otten JJ, Heeneman S, Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner. PLoS One 2013 8 e55784. doi: 10.1371/journal.pone.0055784
32. Kastl SP, Speidl WS, Katsaros KM, Kaun C, Rega G, Assadian A, Hagmueller GW, Hoeth M, de Martin R, Ma Y, Maurer G, Huber K, Wojta J, Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. Blood 2009 114 2812 2818. doi: 10.1182/blood-2009-01-200915
33. Massberg S, Gawaz M, Grüner S, Schulte V, Konrad I, Zohlnhöfer D, Heinzmann U, Nieswandt B, A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 2003 197 41 49
34. Aihara K, Azuma H, Akaike M, Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice. J Clin Invest 2007 117 1514 1526. doi: 10.1172/JCI27095
35. Jiang D, Liang J, Fan J, Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005 11 1173 1179. doi: 10.1038/nm1315
36. Wight TN, Merrilees MJ, Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 2004 94 1158 1167. doi: 10.1161/01.RES.0000126921.29919.51
37. Ameye L, Young MF, Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology 2002 12 107R 116R
38. Xu T, Bianco P, Fisher LW, Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet 1998 20 78 82. doi: 10.1038/1746
39. Skålén K, Gustafsson M, Rydberg EK, Hultén LM, Wiklund O, Innerarity TL, Borén J, Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002 417 750 754. doi: 10.1038/nature00804
40. O'Brien KD, Lewis K, Fischer JW, Johnson P, Hwang JY, Knopp EA, Kinsella MG, Barrett PH, Chait A, Wight TN, Smooth muscle cell biglycan overexpression results in increased lipoprotein retention on extracellular matrix: implications for the retention of lipoproteins in atherosclerosis. Atherosclerosis 2004 177 29 35. doi: 10.1016/j.atherosclerosis.2004.07.007
41. Thompson JC, Tang T, Wilson PG, Yoder MH, Tannock LR, Increased atherosclerosis in mice with increased vascular biglycan content. Atherosclerosis 2014 235 71 75. doi: 10.1016/j.atherosclerosis.2014.03.037
42. Talusan P, Bedri S, Yang S, Kattapuram T, Silva N, Roughley PJ, Stone JR, Analysis of intimal proteoglycans in atherosclerosis-prone and atherosclerosis-resistant human arteries by mass spectrometry. Mol Cell Proteomics 2005 4 1350 1357. doi: 10.1074/mcp.M500088-MCP200